M

Moderna

Develops mRNA-based medicines for health

Principal Specialist Quality Assurance Tech Operations

Full-TimeUpdated on 10/23/2026
No salary listed
Senior
Bachelor's
Melbourne VIC, Australia
In Person70% in-office work model.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree in a science or engineering discipline, or an equivalent combination of education and experience.
  • At least 5 years of pharmaceutical quality, validation, or related Good Manufacturing Practice (GMP) experience.
  • Experience with equipment qualification, process validation, and validation lifecycle management in a GMP-regulated environment.
  • Experience with deviations, investigations, corrective and preventive actions (CAPAs), change controls, and risk assessments.
  • Experience supporting quality control (QC) laboratory validations, investigations, and escalation in a GMP-regulated environment.
  • Demonstrated risk-based decision-making and strong technical writing for GMP and validation documentation.
  • Strong cross-functional communication skills and experience supporting audits and inspections.
Responsibilities
  • Provide quality oversight across manufacturing operations, technology transfer activities, GMP facility initiatives, and QC laboratory quality support, with primary responsibility for drug product validation, including equipment qualification, process validation, lifecycle validation management, analytical method validation, and associated laboratory validation activities.
  • Provide quality oversight for commissioning, qualification, and validation of manufacturing equipment, systems, facilities, and critical utilities.
  • Support the full process validation lifecycle, including validation strategy, process performance qualification (PPQ), continued process verification (CPV), and management of changes impacting validated state.
  • Provide quality assurance oversight for QC laboratory validation activities, including equipment qualification, laboratory system changes, and validation activities affecting product quality or validated state.
  • Lead or support quality review of QC laboratory investigations, deviations, CAPAs, and change controls, ensuring timely, scientifically sound assessment and resolution.
  • Act as the primary quality assurance escalation point for technical, operational, validation, and QC laboratory issues, applying risk-based decision-making to support effective resolutions.
  • Review and approve validation documentation, including protocols, reports, discrepancy assessments, change controls, and risk assessments, ensuring alignment with site and global quality system requirements.
  • Provide quality oversight for product technology transfers, process implementation activities, and technical changes impacting manufacturing processes, validated systems, and QC laboratory operations.
  • Ensure manufacturing and supporting activities are executed in accordance with approved procedures, validated process parameters, equipment qualification requirements, and established control strategies.
  • Lead or support quality review of deviations, investigations, CAPAs, and change controls relating to validation, manufacturing processes, technical operations, and QC laboratory activities.
  • Partner with Operations, Manufacturing Sciences & Technology (MS&T), Engineering, Facilities, QC, Supply Chain, and Quality teams to identify, assess, and manage validation, process, laboratory, compliance, and operational risks.
  • Apply Quality Risk Management principles to technical assessments, change evaluations, deviation investigations, escalation decisions, and activities affecting product quality or validated state.
  • Review and approve GMP documentation, including standard operating procedures (SOPs), specifications, technical reports, validation protocols, validation summary reports, forms, and associated quality records.
  • Support GMP material release activities and batch disposition, where applicable.
  • Contribute to inspection and audit readiness through participation in internal audits, client audits, and regulatory inspections.
  • Lead or support the preparation of inspection responses and implementation of remediation actions arising from audit or regulatory observations.
  • Maintain a strong floor presence, providing visible quality assurance oversight to ensure compliance with GMP requirements, validated operating practices, approved procedures, and documentation standards.
  • Coach manufacturing and support teams on validation principles, documentation practices, investigation quality, and risk-based quality expectations to strengthen operational execution and quality culture.
  • Drive continuous improvement of validation systems, technical quality processes, laboratory quality support, and operational readiness to enhance compliance, robustness, and efficiency.
  • Support the development of quality assurance team members and contribute to building technical capability across the Quality function.
  • Provide technical judgment, collaborative leadership, and visible quality assurance partnership to ensure the ongoing quality and compliance of Moderna's manufacturing operations in Australia.
Desired Qualifications
  • Experience supporting sterile drug product manufacturing.
  • Experience with process performance qualification, continued process verification, and drug product equipment qualification.
  • Experience supporting QC laboratory equipment qualification and GMP laboratory quality systems.
  • Experience applying formal quality risk management methodologies to process, equipment, system, or laboratory changes.
  • Experience supporting technology transfer, startup, or commissioning in a highly regulated manufacturing environment.

About the company

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Get referred to Moderna

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 convertible notes raised $3 billion for oncology growth and debt flexibility.
  • April 21, 2026 European Commission approval made mCombriax the first authorized flu-COVID combo vaccine.
  • Second-quarter 2026 guidance targets up to 10% revenue growth and year-end cash of $4.7 billion.

What critics are saying

  • September 28, 2026, Delaware kept Bayer's mRNA patent case alive against Moderna.
  • July 15, 2026, Sanofi sued Moderna over COVID vaccine patents in New Jersey.
  • If intismeran fails beyond melanoma, Moderna remains a shrinking vaccine company.

What makes Moderna unique

  • Moderna's mRNA platform spans vaccines, oncology, and rare disease, unlike one-product peers.
  • September 30, 2026, Moderna added a COO to scale intismeran autogene manufacturing.
  • Bancel says Moderna owns mutation-selection software for personalized vaccines and synthetic, cell-free production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Sabbatical Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 23rd, 2026
Moderna sees $114.9M in net ETF buying as CGGO adds $121.1M stake

ETFs bought $114.9 million of Moderna stock on Wednesday, October 21, ending a one-day net selling streak. Twenty ETFs were buyers and 10 were sellers. CGGO led with 492,604 shares worth $121.1 million, a 1.06% portfolio weight. IBB added $2.0 million and QQQM $1.0 million. The flows followed a $7.5 million net outflow on October 20 and a $26.1 million net inflow on October 19. Over the last five reported days, ETFs were net buyers on three and net sellers on two. Moderna has a market cap of $80.9 billion. Its trailing 12-month revenue was $2.23 billion, down 27.3% over one year, and the shares have returned 587.11% so far this year.

Yahoo Finance
Oct 22nd, 2026
Moderna sinks 18% after leak of melanoma vaccine data showing 42% lower recurrence risk

Moderna shares fell 18% after detailed Phase 3 results for its personalised melanoma vaccine, developed with Merck, appeared online two days before their scheduled presentation. The data surfaced on medical news site Oncology Central and was taken down shortly afterwards. Trading in Moderna was halted for volatility. The leaked data still looks positive. Adding the vaccine, intismeran autogene, to Merck's Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. After two years, 82.2% of patients on the combination were alive and cancer-free, against 70% on Keytruda alone. The trial enrolled 1,137 patients. The stock had risen more than eightfold this year, and traded at about 52x forward sales before the drop. The 42% figure also trails the 49% from the smaller Phase 2b trial. Full results are due at the ESMO Congress on Saturday.

Yahoo Finance
Oct 21st, 2026
Moderna soars 600% to $90B market cap, but valuation leaves no margin for error

Moderna (NASDAQ: MRNA) has soared over 600% this year, making it the best performer among large-cap healthcare stocks. Eli Lilly gained 16% and Johnson & Johnson 22%. The rally followed US approval of mFLUSIVA, an influenza vaccine for people aged 50 and older. Moderna also said its personalised cancer vaccine, intismeran autogene, significantly improved recurrence-free survival in certain melanoma patients when combined with Merck's Keytruda. It is the first personalised vaccine to produce positive Phase 3 results. Moderna's market cap now stands at $90 billion. The average analyst price target of $123.61 implies a downside of about 45%. In the first six months of 2026, revenue rose 113.6% to $534 million, but net loss widened to $2.1 billion from $1.8 billion.

Yahoo Finance
Oct 21st, 2026
ServiceNow and Kinder Morgan are large-cap picks to watch; Moderna's $96.65B value underwhelms

StockStory, a stock research service, named two large-cap stocks to watch and one to avoid. It advises steering clear of Moderna, which has a market cap of $96.65 billion. Sales fell 20.5% annually over five years, and earnings per share dropped 24.5% annually. Its free cash flow margin fell 95.9 percentage points. The stock trades at $241.71, or 44.1x forward price-to-sales. ServiceNow ($154.6 billion market cap) grew annual recurring revenue 22.3% over the last year and has a free cash flow margin of 33.4%. It trades at $148.56 per share. Kinder Morgan ($74.75 billion market cap) reported $17.96 billion in revenue. Its shares trade at $33.64, or 22.5x forward earnings.

Yahoo Finance
Oct 19th, 2026
Moderna, Chemed and 10x Genomics: three healthcare stocks to avoid despite a 25.2% sector rally

Healthcare stocks have gained 25.2% over the past six months, beating the S&P 500 by 16.3 percentage points. Even so, StockStory warns that heavy regulation can hurt earnings, and names three stocks to avoid. Moderna, valued at $87.04 billion, has seen sales fall 20.5% a year over five years. Earnings per share dropped 24.5% annually, and the stock trades at 46x forward price-to-sales. Chemed, worth $6.67 billion, grew revenue 4.1% a year over five years, slower than its peers. Its adjusted operating margin fell 3.9 percentage points, and it trades at 20x forward earnings. 10x Genomics, valued at $9.10 billion, saw revenue decline 1.2% annually over two years to $616.9 million. Its returns on capital are negative.